Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Is this real life? Is this just fantasy? Decreased relapse following haploidentical transplant in Hodgkin’s lymphoma with posttransplant cyclophosphamide

Bone Marrow Transplantation volume 55, pages 483–484 (2020)Cite this article

Subjects

In the last few years, brentuximab vedotin and nivolumab rapidly changed the therapeutic strategies for relapsed/refractory Hodgkin lymphoma (HL) [1, 2]. Despite their high efficacy, no plateau curves have been observed in patients treated with these drugs. For this reason, allogeneic hematopoietic stem cell transplant (alloHCT) still represents the standard consolidation option for transplant-eligible patients who failed second line of therapy. Differently from other lymphomas, the use of posttransplant cyclophosphamide (PT-Cy) based graft-versus-host disease (GVHD) prophylaxis seems to improve not only the incidence of chronic GVHD but also the relapse incidence.

In the paper by Dr Rivas et al., we have another evidence that alloHCT could allow relapsed/refractory HL patients to reach a prolonged survival and, hopefully, to be cured from their disease [3]. Moreover, in line with current reports, the use of haploidentical donors (with PT-Cy GVHD prophylaxis) showed similar results as matched-related or matched-unrelated donors with calcineurine inhibitors based GVHD prophylaxis [4,5,6]. Curiously, the use of a haploidentical donor was associated to a higher progression-free survival possibly due to a decreased relapse incidence.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183–9.

    Article  CAS  Google Scholar 

  2. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311–9.

    Article  Google Scholar 

  3. Rivas MM, Berro M, Prates MV. Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment. Bone Marrow Transpl. 2019. https://doi.org/10.1038/s41409-019-0640-z [Epub ahead of print].

  4. Burroughs LM, O’Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ. et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory hodgkin lymphoma. Biol Blood Marrow Transpl. 2008;14:1279–87.

    Article  Google Scholar 

  5. Ahmed S, Kanakry JA, Ahn KW, Litovich C, Abdel-Azim H, Aljurf M, et al. Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide–based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for hodgkin lymphoma. Biol Blood Marrow Transpl. 2019;25:1859–68.

    Article  Google Scholar 

  6. Gauthier J, Poiré X, Gac AC, Leclerc M, Guillaume T, Chalandon Y, et al. Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin’s lymphoma undergoing allogeneic haematopoietic cell transplantation—a study by the Francophone society of bone marrow transplantation and cellular therapy. Bone Marrow Transpl. 2018;53:400–9.

  7. Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009;94:230–8.

    Article  Google Scholar 

  8. De Philippis, C, Legrande, F, Bramant, S. Checkpoint inhibitor treatment before haploidentical transplantation in relapsed or refractory Hodgkin’s lymphoma (HL) patients is associated with higher PFS without increased toxicities. EBMT. 2019. https://doi.org/10.1038/s41409-019-0561-x.

  9. Matthias JQ, Misiewicz JJ, Scott RB. Cyclophosphamide in Hodgkin’s disease and related disorders. Brit Med J. 1960;2:1837–40.

    Article  CAS  Google Scholar 

  10. Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, Chhabra S, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127:938–47.

    Article  CAS  Google Scholar 

  11. Mariotti J, Devillier R, Bramanti S, Giordano L, Sarina B, Furst S, et al. Peripheral blood stem cells versus bone marrow for T cell–replete haploidentical transplantation with post-transplant cyclophosphamide in Hodgkin lymphoma. Biol Blood Marrow Transpl. 2019;25:1810–7.

    Article  CAS  Google Scholar 

  12. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–100.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Hematology Department, Institut Català d’Oncologia-Hospitalet, Institut d’Investigació de Ciències Biomèdiques (IDIBELL), Barcelona, Spain

    A Mussetti & A. Sureda

Authors
  1. A Mussetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Sureda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Sureda.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mussetti, A., Sureda, A. Is this real life? Is this just fantasy? Decreased relapse following haploidentical transplant in Hodgkin’s lymphoma with posttransplant cyclophosphamide. Bone Marrow Transplant 55, 483–484 (2020). https://doi.org/10.1038/s41409-019-0754-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0754-3

Search

Advanced search

Quick links